ArticleFrontiers in medical technology2026
Transcatheter dual-device closure for symptomatic iatrogenic atrial septal defect following bioprosthetic mitral valve replacement: a case report.
Article in Frontiers in medical technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iatrogenic atrial septal defect (iASD) is a relatively common complication after cardiac surgical or catheter-based procedures involving transseptal access. While most defects close spontaneously, a subset may persist and become hemodynamically significant, leading to clinical deterioration and necessitating intervention. We report a case of a large, persistent iASD that led to progressive right-sided heart failure following bioprosthetic mitral valve replacement combined with tricuspid annuloplasty. A 69-year-old male underwent bioprosthetic mitral valve replacement and tricuspid annuloplasty. Postoperatively, the patient developed a large, persistent iASD, which contributed to severe right-sided heart failure. The patient also had end-stage liver disease, portal hypertension, and severe coagulopathy, which made reoperation extremely high-risk. After heart team evaluation, a transcatheter closure approach was chosen. Initially, a 24-mm occluder was deployed, but significant residual shunting remained. A planned two-device strategy was then performed, resulting in complete closure of the defect. Post-procedure imaging confirmed the absence of residual shunt, and tricuspid regurgitation significantly improved. The patient's symptoms improved to New York Heart Association NYHA I-II, and at six-month follow-up, the device remained stable, and cardiac function had recovered. This case illustrates that in patients with large, complex, or poorly rimmed iASDs, particularly those who are not suitable candidates for reoperation, the dual-device strategy represents a safe and effective percutaneous alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.